MEI Pharma, Inc. is an oncology company. The Company is focused on the clinical development of drugs and therapies for treatment of cancer. The Company's portfolio of clinical drug candidates includes Pracinostat, ME-344 and PWT143. Pracinostat is an orally available histone deacetylase (HDAC) inhibitor indicated for the treatment of advanced hematologic diseases, such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). ME-344 is an isoflavone-based mitochondrial inhibitor targeting a mitochondrial component of the terminal respiratory chain complex in rapidly proliferating cells. PWT143 is an oral inhibitor of phosphatidylinositide 3-kinase (PI3K) delta, a molecular target that plays a critical role in the proliferation and survival of hematologic cancer cells. Pracinostat has been tested in multiple Phase I and Phase II clinical trials in advanced hematologic malignancies and solid tumor indications.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:MSHL
- CUSIP: N/A
- Web: www.meipharma.com/
- Trailing P/E Ratio:
- P/E Growth:
- Net Margins: -13.36%
- Return on Equity: -4.40%
- Return on Assets: -4.09%
Frequently Asked Questions for MEI Pharma (NASDAQ:MSHL)
What is MEI Pharma's stock symbol?
MEI Pharma trades on the NASDAQ under the ticker symbol "MSHL."
Who are some of MEI Pharma's key competitors?
Some companies that are related to MEI Pharma include Amgen (AMGN), Celgene Corporation (CELG), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals Incorporated (VRTX), Exelixis (EXEL), BIOVERATIV INC (BIVV), TESARO (TSRO), Kite Pharma (KITE), bluebird bio (BLUE), Neurocrine Biosciences (NBIX), Clovis Oncology (CLVS), Intercept Pharmaceuticals (ICPT), BeiGene (BGNE), Juno Therapeutics (JUNO), Ultragenyx Pharmaceutical (RARE), China Biologic Products (CBPO) and GW Pharmaceuticals PLC (GWPH).
Who are MEI Pharma's key executives?
MEI Pharma's management team includes the folowing people:
- Christine Anna White M.D., Independent Chairman of the Board
- Daniel P. Gold Ph.D., President, Chief Executive Officer, Director
- Thomas M. Zech, Chief Financial Officer, Secretary
- David M. Urso, Senior Vice President of Corporate Development, General Counsel
- Robert D. Mass M.D., Chief Medical Officer
- Charles V. Baltic III, Independent Director
- Kevan E. Clemens Ph.D., Independent Director
- Nicholas R. Glover Ph.D., Independent Director
- Thomas C. Reynolds M.D. Ph.D., Independent Director
- William Dodge Rueckert, Independent Director
How do I buy MEI Pharma stock?
Shares of MEI Pharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is MEI Pharma's stock price today?
MarketBeat Community Rating for MEI Pharma (NASDAQ MSHL)MarketBeat's community ratings are surveys of what our community members think about MEI Pharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of MEI Pharma stock can currently be purchased for approximately $0.42.
Consensus Ratings for MEI Pharma (NASDAQ:MSHL) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for MEI Pharma (NASDAQ:MSHL)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for MEI Pharma (NASDAQ:MSHL)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for MEI Pharma (NASDAQ:MSHL)
Current Year EPS Consensus Estimate: $-0.2600 EPS
Dividend History for MEI Pharma (NASDAQ:MSHL)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for MEI Pharma (NASDAQ:MSHL)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for MEI Pharma (NASDAQ:MSHL)
Latest Headlines for MEI Pharma (NASDAQ:MSHL)
MEI Pharma (MSHL) Chart for Thursday, July, 20, 2017